Epigral Ltd Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
N/A
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Company expects strong volume growth driven by commissioned projects in CPVC Resin, Epichlorohydrin, and Caustic Soda capacity expansions.
- Volume growth was 21% YoY and 12% QoQ in Q2 FY24; 15% growth in first half of FY24.
- Demand for CPVC is expected to grow significantly, easily absorbing new capacities including 45,000 tons planned soon and further expansions by others taking 2-3 years.
- Long-term growth story remains intact; infrastructure and tier 2/3 city projects driving CPVC pipe demand.
- Company targets consistent top-line and bottom-line growth through diversification into multiproduct segments.
- EBITDA margin expected around 24-25% for FY24, with improvement expected in H2 over H1.
- Volume growth of 15-20% annually targeted via continuous CapEx and capacity utilization improvements.
- Expansion plans for Chlorotoluene, CPVC Compound commissioning by Q4 FY24 to contribute from FY25 onward.
See what Epigral Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- As of the Q2 FY24 earnings call, there is no mention of any planned equity fundraising or buybacks.
- The company is focused on growth and CapEx for volume expansion rather than buyback or bonuses.
- Current debt level as of 30th September 2023 stands at INR 961 crore.
- Additional borrowings for Chlorotoluene and CPVC expansions are expected to keep debt in the range of INR 970-980 crore.
- The company expects debt to remain at similar levels, factoring in repayments and new borrowings for ongoing CapEx.
- There is no explicit mention of fresh debt fundraising beyond what's accounted for current expansion projects.
See what Epigral Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Epigral Limited is currently commissioning a CPVC Compound plant with a capacity of 35,000 tons per annum, expected to be operational by the end of Q4 FY24.
- The company is expanding its CPVC capacity from 30,000 to 45,000 tons per annum, with the expanded capacity expected to be completed in Q4 FY24.
- They are also investing in Chlorotoluene plant commissioning and additional Caustic Soda capacity, aiming to increase captive chlorine consumption to 80%.
- Total capital expenditure in Q2 FY24 was INR 117 crore.
- The company plans continued expansions in high-value and high-growth products, strengthening integrated complex and diversifying into multiple industries for consistent growth.
- Debt levels are expected to remain stable around INR 970-980 crore post CapEx completion.
- Volume growth from CPVC expansion and Chlorotoluene plant is expected to drive sales from FY25 onwards.
Track Epigral Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- EBITDA margin guidance for FY24 is expected around 24% to 25%, with improvement in H2 over H1.
- Volume growth is expected to be strong, driven by commissioning of CPVC, Epichlorohydrin, and Caustic Soda expansions.
- CPVC capacity utilization currently at 80-85%, expected to sustain and grow as new capacities come online.
- Epichlorohydrin capacity utilization improved to ~45-50% and expected to increase further in coming quarters.
- Demand for CPVC is expected to remain strong, especially in Q2 and Q3, supporting volume growth.
- Contribution from Derivatives and Specialty segment is increasing (46% of revenue in Q2 FY24 vs 29% in Q2 FY23), supporting margin expansion.
- PAT grew 20% QoQ in Q2 despite YoY challenges, indicating recovery.
- Long-term revenue growth target remains INR 5,000 crore by FY27, with 15-20% annual volume growth aspirations.
- Management expects recovery and consistent growth post short-term industry challenges.
Order book
How does Epigral Ltd rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Epigral Ltd rank in Chemicals & Petrochemicals?
Compare Epigral Ltd against every Chemicals & Petrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Epigral Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…